---
title: "Driven by the priority granted by the U.S. Food and Drug Administration, Revolution Medicines' stock"
description: "Driven by the priority granted by the U.S. Food and Drug Administration, Revolution Medicines' stock price surged 13% in after-hours trading"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261508838.md"
published_at: "2025-10-16T21:14:51.000Z"
---

# Driven by the priority granted by the U.S. Food and Drug Administration, Revolution Medicines' stock

> Driven by the priority granted by the U.S. Food and Drug Administration, Revolution Medicines' stock price surged 13% in after-hours trading

Driven by the priority granted by the U.S. Food and Drug Administration, Revolution Medicines' stock price surged 13% in after-hours trading

### Related Stocks

- [RVMD.US - Revolution Medicines](https://longbridge.com/en/quote/RVMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Revolution Medicines COO Margaret Horn Reports Disposal of Common Shares | Margaret A. Horn, COO of Revolution Medicines Inc., has reported the disposal of common shares of the company. The detai | [Link](https://longbridge.com/en/news/270209739.md) |
| Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers | Revolution Medicines Inc. has updated its clinical pipeline for RAS-addicted cancers, reporting over 2,500 patients trea | [Link](https://longbridge.com/en/news/272308108.md) |
| FDA Grants Breakthrough Therapy Designation to Revolution Medicines' Zoldonrasib for KRAS G12D-Mutated NSCLC | Revolution Medicines Inc. announced that the FDA has granted Breakthrough Therapy Designation to zoldonrasib, a selectiv | [Link](https://longbridge.com/en/news/271936850.md) |
| Revolution Medicines Launches Phase 3 Trial of Daraxonrasib in Resectable Pancreatic Cancer | Revolution Medicines Inc. has initiated a Phase 3 clinical trial, RASolute 304, for daraxonrasib in patients with resect | [Link](https://longbridge.com/en/news/270162709.md) |
| BUZZ-Revolution climbs after report of Merck's up to $32 bln buyout talks | Shares of Revolution Medicinesrose 15% to $123.49 in premarket trading following reports of Merck's potential buyout tal | [Link](https://longbridge.com/en/news/272066978.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.